Abeona Therapeutics
ABEO
48 hedge funds and large institutions have $70.9M invested in Abeona Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 6 closing their positions.
964% more call options, than puts
Call options by funds: $3.22M | Put options by funds: $303K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
35% more capital invested
Capital invested by funds: $52.5M → $70.9M (+$18.4M)
20% more funds holding
Funds holding: 40 → 48 (+8)
6.76% more ownership
Funds ownership: 50.39% → 57.15% (+6.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.64M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$2.57M |
| 3 |
Millennium Management
New York
|
+$1.87M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.53M |
| 5 |
Walleye Capital
New York
|
+$827K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.85M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.53M |
| 3 |
Barclays
London,
United Kingdom
|
-$887K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$648K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$373K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
51
GSA Capital Partners
London,
United Kingdom
| – | -$49K | -11,638 | Closed |
|
52
Dimensional Fund Advisors
Austin,
Texas
| – | -$47.1K | -11,196 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$4.47K | -1,061 | Closed |
|
|
CT
54
Cambridge Trust
Cambridge,
Massachusetts
| – | -$55 | -13 | Closed |
|
ABEO Hedge Fund Activity: Q4 2023 in Review
48 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2023, worth a combined $70.9M — up 35% from $52.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ABEO positions and 6 closed out — a net gain of 8 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.64M. The largest seller was Point72 Asset Management, cutting an estimated $1.85M.
- 48 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2023, up from 40 in Q3 2023.
- Funds reported $70.9M of Abeona Therapeutics stock for Q4 2023, up 35% quarter-over-quarter.
- 14 funds opened new Abeona Therapeutics positions in Q4 2023 and 6 closed out, a net change of +8 holders.
- The largest Abeona Therapeutics buyer in Q4 2023 was Ikarian Capital, an estimated $2.64M added.
- The largest Abeona Therapeutics seller in Q4 2023 was Point72 Asset Management, an estimated $1.85M sold.
Based on aggregated 13F filings for Q4 2023.